Mnemo Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mnemo Therapeutics - overview
Established
2019
Location
Paris, -, France
Primary Industry
Biotechnology
About
Founded in 2019 and based in Paris, France, Mnemo Therapeutics is a biotechnology company that focuses on the development of cell therapies. The firm was founded by Alain Maiore and has raised EUR 75 million in Series A funding in June 2021. Mnemo Therapeutics uses the EnfiniT platform, a drug discovery engine that integrates cell therapy through the identification of antigens classes. Mnemo Therapeutics plans to use its Series A funding to accelerate the development of its platform and chimeric antigen receptors (CAR) T cell therapy platform combining research from Institut Curie and Memorial Sloan Kettering Cancer Center (MSK).
Current Investors
Sofinnova Partners, Alexandria Venture Investments, Redmile Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.mnemo-tx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.